Bayer’s Legal Victory Opens a Window—But Cash Burn and a New Patent Fight Threaten to Slam It Shut
Veröffentlicht: 01.07.2026 um 17:14 Uhr, Redaktion boerse-global.de
Bayer’s stock has nearly doubled over the past twelve months, but the rally masks a delicate balancing act. A landmark US Supreme Court ruling in late June wiped out the vast majority of glyphosate lawsuits, sending shares soaring more than 20% in a week. Yet the company is simultaneously burning billions in legal settlements, fighting a new court battle with Johnson & Johnson over a key cancer drug, and racing to replace its ageing blockbuster Xarelto before patents expire. The next six weeks will determine whether the pharma and agrochemical group can turn its legal win into a lasting financial turnaround.
A Supreme Court Tailwind—With Exceptions
The Supreme Court ruled on June 25 that federal law preempts most state-law claims that glyphosate-based herbicides lack adequate cancer warnings, provided the product has been reviewed by the Environmental Protection Agency. Bayer welcomed the decision as a breakthrough after years of litigation over Roundup. However, the ruling leaves two major categories intact: “design defect” allegations and negligence claims. Trial lawyers are already probing new legal avenues, meaning tens of thousands of existing cases may not be extinguished entirely.
The stock responded explosively. At its recent price of €48.33, the shares have gained 21.16% in seven days, 37.34% in a month, and 83.07% over the past year. That puts them just 3.20% below the 52-week high of €49.93 set on February 17, 2026. But the technical picture is flashing caution: the 14-day relative strength index stands at 79.9, deep in overbought territory, while the 30-day annualised volatility has hit 59.45%.
A Rivalry Over Prostate Cancer
While the legal clouds are thinning over Roundup, a different sort of legal storm is brewing in oncology. Bayer has sued Johnson & Johnson in New York, accusing its rival of misleading advertising for its prostate-cancer drug Erleada. J&J claims Erleada reduces the risk of death by 51% more than Bayer’s Nubeqa—a comparison Bayer says is scientifically unsound.
Should investors sell immediately? Or is it worth buying Bayer?
In mid-June, Bayer escalated the lawsuit, demanding damages and an immediate halt to the ad campaign. The court has noted methodological weaknesses in J&J’s data, but Bayer still lacks access to the full clinical trial results, which J&J has kept sealed. The stakes are high: Nubeqa is one of Bayer’s fastest-growing assets, with first-quarter sales jumping 57% year-on-year to €2.4 billion. More than 200,000 patients worldwide are now on the drug.
The Settlement Clock Is Ticking
Bayer’s most immediate legal deadline is a $7.25 billion settlement package designed to resolve a large portion of the outstanding Roundup claims. A final hearing on the proposal had been scheduled for July 9, but the court has pushed it back to August 19, extending the period of uncertainty for investors. Even if approved, the settlement does not cover design-defect or negligence cases, leaving a residual risk that could still drain cash for years.
The cash drain is already visible. Bayer estimates that litigation payouts for 2026 will total roughly €5 billion, which is expected to push free cash flow as deep as minus €2.5 billion. Net financial debt stood at €32.5 billion at the end of March, up 9% from the start of the year. Servicing that debt while continuing to fund R&D and pay settlements is the central challenge for CEO Bill Anderson.
Pharma Pipeline Under the Microscope
Operationally, the picture is more encouraging—but fragile. First-quarter revenue rose 4.1% on a currency-adjusted basis to €13.4 billion, led by pharmaceuticals. Drugs such as Nubeqa (up 57%) and the kidney-disease treatment Kerendia (up 84%) are growing fast. The pipeline’s next big hope is Asundexian, a stroke-prevention drug that has been granted accelerated review in China and the US, with the European Medicines Agency also examining the application. Clinical data showed a 26% reduction in ischemic stroke risk.
But the patent expiry of Xarelto, Bayer’s former top-selling anticoagulant, is approaching quickly. Asundexian must fill the gap. To speed up discovery, Bayer has partnered with Iambic Therapeutics to deploy artificial intelligence in identifying new molecules, aiming to shorten the traditional multi-billion-dollar development cycle.
Cost Cuts and the Path to Positive Cash Flow
Management is counting on a major restructuring programme, dubbed “Dynamic Shared Ownership”, to reduce bureaucracy and save €2 billion annually starting this year. The plan includes flattening management layers and streamlining decision-making. Yet analysts are demanding visible progress on free cash flow before they turn more bullish. Bayer itself expects free cash flow to remain negative for the full year, and the inflection point is not expected before 2027.
Bayer at a turning point? This analysis reveals what investors need to know now.
The agriculture division, meanwhile, is pursuing its own efficiency gains through the “CropKey” development programme, which aims to bring new crop-protection products to market faster. The division remains a core profit driver, though its performance is more cyclical than pharma.
What Comes Next
Two dates will dominate the near-term outlook. On August 4, Bayer reports second-quarter results. The market will scrutinise revenue trends, litigation cash outflows, and any update on the debt trajectory. On August 19, the final hearing on the $7.25 billion settlement will take place. If the judge approves the deal and Bayer can show that free cash flow is on track to improve, the stock may sustain its rally. If the settlement stalls or quarterly numbers disappoint, the overbought RSI and stretched distance from moving averages (the stock is now 26% above its 50-day average and 31% above its 200-day average) could trigger a sharp pullback.
For now, Bayer has momentum on its side, but the runway is narrow. The legal victory buys time, but it does not solve the structural problem of a balance sheet strained by settlements and an array of legacy liabilities. The next few weeks will show whether the operative business can generate enough force to lift the company clear of its past.
Ad
Bayer Stock: New Analysis - 1 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
